Asthma Clinical Trial
Official title:
Distributed Asthma Learning Initiative
The National Heart, Lung, and Blood Institute (NHLBI) has established guidelines for treating people with asthma. This study will evaluate the effectiveness of a distance learning program that aims to educate doctors on these guidelines, specifically the use of inhaled corticosteroids to treat asthma in pediatric patients.
Asthma is a long-term lung disease that affects more than 22 million people in the United
States. Symptoms include wheezing, chest tightness, shortness of breath, and coughing.
Inhaled corticosteroids are a common medication used to treat asthma. NHLBI has established
guidelines for doctors to reference when treating people with asthma. Study researchers
previously evaluated a distance learning program aimed to educate doctors on the NHLBI
guidelines and to improve pediatrician adherence to the guideline recommendations for the
use of daily inhaled corticosteroids for persistent asthma in pediatric patients. This pilot
study will evaluate a new version of the distance learning program. By using a distance
learning program rather than a traditional face-to-face educational program, participants
will be able to complete the program on their own schedule, and this flexibility may result
in increased interest in the program. The purpose of this study is to evaluate the
effectiveness of the new distance learning program on changing pediatricians' behavior,
attitudes, and knowledge regarding the NHLBI guidelines for the use of inhaled
corticosteroids to treat pediatric patients with asthma.
This study will enroll pediatricians. Participants will be randomly assigned to either the
distance learning group or a control group. At baseline, all participants will complete
questionnaires. Participants in the control group will not take part in any of the
educational activities. Participants in the distance learning group will take part in a
1-hour Webinar, or teleconference, that will provide an orientation to the program and
discuss the importance of the NHLBI guidelines. At any time between the first Webinar and a
6-week follow-up Webinar, participants will log into the study Web site and complete a
training module that aims to educate participants on common barriers to prescribing daily
inhaled corticosteroids. As an alternative to the Web site, participants may choose to view
the training module on a CD-ROM. Six weeks after the first Webinar, participants will take
part in a follow-up Webinar. At this time, study researchers will answer participants'
questions and provide a program review. The Web site and study materials will remain
available to participants in the distance learning group for 6 months after the follow-up
Webinar; a list serve will also be made available to participants. At 1 and 6 months after
the follow-up Webinar, all participants will complete questionnaires.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|